On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.
Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."
Data provided by Nasdaq. Minimum 15 minutes delayed.
August 07, 2018
Nuvectra™ Reports Second Quarter 2018 Financial Results
Reports Record Algovita® Sales of $11.5 million, Up 110% YoY PLANO, Texas, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended June 30, 2018. Highlights Reported record consolidated revenues of $13.1 million for the second quarter 2018. Reached approximately 60 active territories for U.S. Algovita. Submitted Virtis™ response to FDA, initiated new 180-day r
August 02, 2018
Nuvectra™ Appoints Neuromodulation Veteran Ben Tranchina as Chief Technology Officer
PLANO, Texas, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the appointment of Ben Tranchina as Chief Technology Officer (CTO), effective August 24, 2018. Mr. Tranchina has over 25 years of industry experience and most relevantly served as VP, Product Development at St. Jude Medical, where he led the development of the company’s neuromodulation portfolio, following his time at Advanced Neuromodulation Systems,
The Ruth Group
|There are currently no events scheduled.|